Compass Therapeutics Stock Technical Analysis
| CMPX Stock | USD 6.52 0.30 4.82% |
As of the 7th of February, Compass Therapeutics shows the Downside Deviation of 3.33, mean deviation of 3.04, and Risk Adjusted Performance of 0.2. Compass Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Compass Therapeutics Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Compass, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to CompassCompass Therapeutics' Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.Compass Therapeutics Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 13.46 | Strong Buy | 9 | Odds |
Most Compass analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Compass stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Compass Therapeutics, talking to its executives and customers, or listening to Compass conference calls.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Compass Therapeutics. Projected growth potential of Compass fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Compass Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Compass Therapeutics is measured differently than its book value, which is the value of Compass that is recorded on the company's balance sheet. Investors also form their own opinion of Compass Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Compass Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Compass Therapeutics' market value can be influenced by many factors that don't directly affect Compass Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Compass Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Compass Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Compass Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Compass Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Compass Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Compass Therapeutics.
| 11/09/2025 |
| 02/07/2026 |
If you would invest 0.00 in Compass Therapeutics on November 9, 2025 and sell it all today you would earn a total of 0.00 from holding Compass Therapeutics or generate 0.0% return on investment in Compass Therapeutics over 90 days. Compass Therapeutics is related to or competes with Fulcrum Therapeutics, 4D Molecular, Ocugen, Bicycle Therapeutics, Gossamer Bio, Lexicon Pharmaceuticals, and Monopar Therapeutics. Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-... More
Compass Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Compass Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Compass Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.33 | |||
| Information Ratio | 0.2151 | |||
| Maximum Drawdown | 16.9 | |||
| Value At Risk | (5.14) | |||
| Potential Upside | 7.61 |
Compass Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Compass Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Compass Therapeutics' standard deviation. In reality, there are many statistical measures that can use Compass Therapeutics historical prices to predict the future Compass Therapeutics' volatility.| Risk Adjusted Performance | 0.2 | |||
| Jensen Alpha | 0.8409 | |||
| Total Risk Alpha | 0.527 | |||
| Sortino Ratio | 0.2488 | |||
| Treynor Ratio | 1.09 |
Compass Therapeutics February 7, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.2 | |||
| Market Risk Adjusted Performance | 1.1 | |||
| Mean Deviation | 3.04 | |||
| Semi Deviation | 2.69 | |||
| Downside Deviation | 3.33 | |||
| Coefficient Of Variation | 419.37 | |||
| Standard Deviation | 3.85 | |||
| Variance | 14.8 | |||
| Information Ratio | 0.2151 | |||
| Jensen Alpha | 0.8409 | |||
| Total Risk Alpha | 0.527 | |||
| Sortino Ratio | 0.2488 | |||
| Treynor Ratio | 1.09 | |||
| Maximum Drawdown | 16.9 | |||
| Value At Risk | (5.14) | |||
| Potential Upside | 7.61 | |||
| Downside Variance | 11.07 | |||
| Semi Variance | 7.25 | |||
| Expected Short fall | (3.57) | |||
| Skewness | 0.3347 | |||
| Kurtosis | (0.31) |
Compass Therapeutics Backtested Returns
Compass Therapeutics appears to be slightly risky, given 3 months investment horizon. Compass Therapeutics secures Sharpe Ratio (or Efficiency) of 0.2, which signifies that the company had a 0.2 % return per unit of risk over the last 3 months. By analyzing Compass Therapeutics' technical indicators, you can evaluate if the expected return of 0.77% is justified by implied risk. Please makes use of Compass Therapeutics' Downside Deviation of 3.33, risk adjusted performance of 0.2, and Mean Deviation of 3.04 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Compass Therapeutics holds a performance score of 15. The firm shows a Beta (market volatility) of 0.83, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Compass Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Compass Therapeutics is expected to be smaller as well. Please check Compass Therapeutics' treynor ratio, as well as the relationship between the expected short fall and day median price , to make a quick decision on whether Compass Therapeutics' price patterns will revert.
Auto-correlation | 0.54 |
Modest predictability
Compass Therapeutics has modest predictability. Overlapping area represents the amount of predictability between Compass Therapeutics time series from 9th of November 2025 to 24th of December 2025 and 24th of December 2025 to 7th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Compass Therapeutics price movement. The serial correlation of 0.54 indicates that about 54.0% of current Compass Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.54 | |
| Spearman Rank Test | 0.54 | |
| Residual Average | 0.0 | |
| Price Variance | 0.27 |
Compass Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Compass Therapeutics Technical Analysis
The output start index for this execution was fifty with a total number of output elements of eleven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Compass Therapeutics volatility. High ATR values indicate high volatility, and low values indicate low volatility.
About Compass Therapeutics Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Compass Therapeutics on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Compass Therapeutics based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Compass Therapeutics price pattern first instead of the macroeconomic environment surrounding Compass Therapeutics. By analyzing Compass Therapeutics's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Compass Therapeutics's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Compass Therapeutics specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2023 | 2024 | 2025 | 2026 (projected) | Current Ratio | 19.73 | 14.96 | 13.46 | 8.59 | Net Debt To EBITDA | 0.46 | 0.67 | 0.77 | 1.06 |
Compass Therapeutics February 7, 2026 Technical Indicators
Most technical analysis of Compass help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Compass from various momentum indicators to cycle indicators. When you analyze Compass charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.2 | |||
| Market Risk Adjusted Performance | 1.1 | |||
| Mean Deviation | 3.04 | |||
| Semi Deviation | 2.69 | |||
| Downside Deviation | 3.33 | |||
| Coefficient Of Variation | 419.37 | |||
| Standard Deviation | 3.85 | |||
| Variance | 14.8 | |||
| Information Ratio | 0.2151 | |||
| Jensen Alpha | 0.8409 | |||
| Total Risk Alpha | 0.527 | |||
| Sortino Ratio | 0.2488 | |||
| Treynor Ratio | 1.09 | |||
| Maximum Drawdown | 16.9 | |||
| Value At Risk | (5.14) | |||
| Potential Upside | 7.61 | |||
| Downside Variance | 11.07 | |||
| Semi Variance | 7.25 | |||
| Expected Short fall | (3.57) | |||
| Skewness | 0.3347 | |||
| Kurtosis | (0.31) |
Compass Therapeutics February 7, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Compass stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 120,029 | ||
| Daily Balance Of Power | 0.75 | ||
| Rate Of Daily Change | 1.05 | ||
| Day Median Price | 6.49 | ||
| Day Typical Price | 6.50 | ||
| Price Action Indicator | 0.18 |
Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.